A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma
Sponsor: University of Texas Southwestern Medical Center
This PHASE1 trial investigates Rectal Adenocarcinoma and is currently completed. University of Texas Southwestern Medical Center leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .